These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38784689)

  • 1. Safety and Effectiveness of Liv.52 DS in Patients With Varied Hepatic Disorders: An Open-Label, Multi-centre, Phase IV Study.
    Shivnitwar SK; Gilada I; Rajkondawar AV; Ojha SK; Katiyar S; Arya N; Babu UV; Kumawat R
    Cureus; 2024 May; 16(5):e60898. PubMed ID: 38784689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
    J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoprotective activity of six polyherbal formulations in paracetamol induced liver toxicity in mice.
    Girish C; Koner BC; Jayanthi S; Rao KR; Rajesh B; Pradhan SC
    Indian J Med Res; 2009 May; 129(5):569-78. PubMed ID: 19675387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease.
    Ivashkin VT; Maevskaya MV; Kobalava ZD; Uspenskiy YP; Fominih JA; Rozanov AV; Tolkacheva VV; Sotnikova TI; Alikhanov BA; Gorbacheva IA; Ershova OB; Znakhyrenko AA; Sokolov KA; Sander-Struckmeier S
    Minerva Gastroenterol Dietol; 2018 Sep; 64(3):208-219. PubMed ID: 29431335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation.
    Huber Y; Boyle M; Hallsworth K; Tiniakos D; Straub BK; Labenz C; Ruckes C; Galle PR; Romero-Gómez M; Anstee QM; Schattenberg JM;
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2085-2092.e1. PubMed ID: 30580090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
    Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
    JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study.
    Shawkat H; Yakoot M; Shawkat T; Helmy S
    Drug Des Devel Ther; 2015; 9():799-804. PubMed ID: 25709404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the chronic liver disease questionnaire in Serbian patients.
    Popovic DDj; Kovacevic NV; Kisic Tepavcevic DB; Trajkovic GZ; Alempijevic TM; Spuran MM; Krstic MN; Jesic RS; Younossi ZM; Pekmezovic TD
    World J Gastroenterol; 2013 Aug; 19(30):4950-7. PubMed ID: 23946600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatoprotective Effect of A Polyherbal Extract Containing Andrographis Paniculata, Tinospora Cordifolia and Solanum Nigrum Against Paracetamol Induced Hepatotoxicity.
    Singh DP; Awasthi H; Luqman S; Singh S; Mani D
    Pharmacogn Mag; 2015 Oct; 11(Suppl 3):S375-9. PubMed ID: 26929570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders.
    Makino I; Nakamura K; Sato Y; Sato Y; Sezai S; Ikeda Y; Shinmura W; Watahiki H; Yamamoto H; Hioki Y; Suzuki M; Kumada T; Honda T; Rikitoku T; Hisanaga Y; Fukui H; Yamao J; Kawasaki H; Hosoda A; Onji M; Matsui H; Sata M; Torimura T; Oho K; Maekawa R; Takagi Y; Shakado S; Nakayama M; Gondo K; Fukushima H; Kusaba T; Tsubouchi H; Hayashi K; Hori T; Iida Y; Yutoku K; Maetani N; Kubo Y; Miyata Y
    Curr Ther Res Clin Exp; 2006 Jan; 67(1):1-20. PubMed ID: 24678081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].
    Qiu LX; Yu HB; Lin W; Liu YR; Qiu YD; Hu ZJ; Pang XH; Zhang J; Liu YL
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):395-401. PubMed ID: 35545564
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic safety of itraconazole.
    Gupta AK; Chwetzoff E; Del Rosso J; Baran R
    J Cutan Med Surg; 2002; 6(3):210-3. PubMed ID: 11951124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
    Francque SM; Hodge A; Boursier J; Younes ZH; Rodriguez-Araujo G; Park GS; Alkhouri N; Abdelmalek MF
    Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia.
    Maev IV; Samsonov AA; Palgova LK; Pavlov CS; Shirokova EN; Vovk EI; Starostin KM
    BMJ Open Gastroenterol; 2020; 7(1):e000368. PubMed ID: 32337059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ayurvedic formulation of Liv-Pro-08 reduces nonalcoholic fatty liver disease in rats fed with high-fat diet.
    Suriyavathana Vedanarayanan M; Krishnan N
    J Acupunct Meridian Stud; 2011 Dec; 4(4):236-41. PubMed ID: 22196506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.